Technical Analysis for CTMX - CytomX Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.05 | 5.45% | 0.05 |
CTMX closed up 5.45 percent on Friday, November 1, 2024, on 2.15 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 5.45% | |
| Narrow Range Bar | Range Contraction | 5.45% | |
| Lower Bollinger Band Walk | Weakness | 5.45% | |
| Gapped Up | Strength | 5.45% | |
| Oversold Stochastic | Weakness | 5.45% | |
| New 52 Week Closing Low | Bearish | 5.85% | |
| Lower Bollinger Band Walk | Weakness | 5.85% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 19 hours ago |
| 10 DMA Resistance | about 19 hours ago |
| 2x Volume Pace | about 19 hours ago |
| 1.5x Volume Pace | about 19 hours ago |
| Up 5% | about 19 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Monoclonal Antibody Therapy Immunogen Oncology Focused Biopharmaceutical
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Compugen Monoclonal Antibody Therapy Immunogen Oncology Focused Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.85 |
| 52 Week Low | 0.9882 |
| Average Volume | 672,305 |
| 200-Day Moving Average | 1.63 |
| 50-Day Moving Average | 1.16 |
| 20-Day Moving Average | 1.10 |
| 10-Day Moving Average | 1.05 |
| Average True Range | 0.05 |
| RSI (14) | 42.20 |
| ADX | 21.38 |
| +DI | 14.05 |
| -DI | 19.98 |
| Chandelier Exit (Long, 3 ATRs) | 1.03 |
| Chandelier Exit (Short, 3 ATRs) | 1.15 |
| Upper Bollinger Bands | 1.23 |
| Lower Bollinger Band | 0.97 |
| Percent B (%b) | 0.31 |
| BandWidth | 23.25 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0079 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.13 | ||||
| Resistance 3 (R3) | 1.12 | 1.09 | 1.12 | ||
| Resistance 2 (R2) | 1.09 | 1.07 | 1.09 | 1.11 | |
| Resistance 1 (R1) | 1.07 | 1.05 | 1.08 | 1.08 | 1.11 |
| Pivot Point | 1.03 | 1.03 | 1.04 | 1.04 | 1.03 |
| Support 1 (S1) | 1.01 | 1.01 | 1.02 | 1.02 | 0.99 |
| Support 2 (S2) | 0.98 | 1.00 | 0.98 | 0.99 | |
| Support 3 (S3) | 0.96 | 0.98 | 0.98 | ||
| Support 4 (S4) | 0.97 |
